Rosacea: an update on therapeutic options

Authors

  • Imran Majid Department of Dermatology, CUTIS Institute of Dermatology, Srinagar, Jammu and Kashmir
  • Shabir Ahmad Bhat Department of Dermatology, JK Health services, Anantnag, Jammu and Kashmir

DOI:

https://doi.org/10.18203/issn.2455-4529.IntJResDermatol20183153

Keywords:

Rosacea, Treatment, Update

Abstract

Rosacea is a common inflammatory skin disease affecting the face usually in middle-aged individuals. The disorder is associated with a lot of psychological impact on the quality of life of the affected patient. Treatment options for this skin disease range from topical treatment options to systemic agents and even lasers. This paper will review the current and some of the upcoming treatment options for this chronic skin disease.

Author Biography

Imran Majid, Department of Dermatology, CUTIS Institute of Dermatology, Srinagar, Jammu and Kashmir

Associate Professor Dermatology

References

Webster GF. Rosacea. Med Clin North Am. 2009;93:1183-94.

Gooderham M. Rosacea and its topical management. Skin Therapy Lett. 2009;14:1-3.

Baldwin HE. Diagnosis and treatment of rosacea: state of the art. J Drugs Dermatol. 2012;11:725-30.

Yamasaki K, Gallo RL. The molecular pathology of rosacea. J Dermatol Sci. 2009;55:77-81.

Wilkin J, Dahl M, Detmar M, Drake L, Feinstein A, Odom R, et al. Standard classification of rosacea: Report of the National Rosacea Society Expert Committee on the Classification and Staging of Rosacea. J Am Acad Dermatol. 2002;46:584-7.

Aksoy B, Altaykan-Hapa A, Egemen D, Karagöz F, Atakan N. The impact of rosacea on quality of life: effects of demographic and clinical characteristics and various treatment modalities. Br J Dermatol. 2010;163:719-25.

Thiboutot D, Thieroff-Ekerdt R, Graupe K. Efficacy and safety of azelaic acid (15%) gel as a new treatment for papulopustular rosacea: results from two vehicle-controlled, randomized phase III studies. J Am Acad Dermatol. 2003;48:836-45.

Thiboutot DM, Fleischer AB Jr, Del Rosso JQ, Graupe K. Azelaic acid 15% gel once daily versus twice daily in papulopustular rosacea. J Drugs Dermatol. 2008;7:541-6.

Gupta AK, Grover MD. Azelaic acid (15% gel) in the treatment of acne rosacea. Int J Dermatol. 2007;46:533-8.

Pye RJ, Burton JL. Treatment of rosacea by metronidazole. Lancet. 1976;1:1211-2.

Yoo Y, Reid DC, Kimball AB. Metronidazole in the treatment of rosacea: do formulation, dosing, and concentration matter? J Drugs Dermatol. 2006;5:317-9.

Nielsen PG. A double-blind study of 1% metronidazole cream versus systemic oxytretracycline therapy for rosacea. Br J Dermatol. 1983;109:63-5.

Maddin A. A comparison of topical azelaic acid 20% cream and topical metronidazole 0.75% cream in the treatment of patients with papulopustular rosacea. J Am Acad Dermatol. 1999;40:961-5.

Elewski BE, Fleischer AB, Jr., Pariser DM. A comparison of 15% azelaic acid gel and 0.75% metronidazole gel in the topical treatment of papulopustular rosacea: results of a randomized trial. Arch Dermatol. 2003;139:1444-50.

Goldman D. Tacrolimus ointment for the treatment of steroid-induced rosacea: a preliminary report. J Am Acad Dermatol. 2001;44:995-8.

Woo DK, James WD. Topical tacrolimus: a review of its uses in dermatology. Dermatitis. 2005;16:6-21.

Pelle MT, Crawford GH, James WD. Rosacea: II. Therapy. J Am Acad Dermatol. 2004;51:499-512.

Garg G, Thami GP. Clinical efficacy of tacrolimus in rosacea. J Eur Acad Dermatol Venereol. 2009;23:239-40.

Kim MB, Kim GW, Park HJ, Kim HS, Chin HW, Kim SH, et al. Pimecrolimus 1% cream for the treatment of rosacea. J Dermatol. 2011;38:1135-9.

Koca R, Altinyazar HC, Ankarali H, Muhtar S, Tekin NS, Cinar S. A comparison of metronidazole 1% cream and pimecrolimus 1% cream in the treatment of patients with papulopustular rosacea: a randomized open-label clinical trial. Clin Exp Dermatol. 2010;35:251-6.

Breneman D, Savin R, VandePol C, Vamvakias G, Levy S, Leyden J. Double-blind, randomized, vehicle controlled clinical trial of once-daily benzoyl peroxide/clindamycin topical gel in the treatment of patients with moderate to severe rosacea. Int J Dermatol. 2004;43:381-7.

Sauder DN, Miller R, Gratton D, Danby W, Griffiths C, Phillips SB. The treatment of rosacea: the safety and efficacy of sodium sulfacetamide 10% and sulfur 5% lotion (Novacet) is demonstrated in a double-blind study. J Dermatolog Treat. 1997;8:79-85.

Koçak M, Yaĝli S, Vahapoĝlu G, Ekşioĝlu M. Permethrin 5% cream versus metronidazole 0.75% gel for the treatment of papulopustular rosacea. A randomized double-blind placebo-controlled study. Dermatology. 2002;205:265-70.

Forstinger C, Kittler H, Binder M. Treatment of rosacea-like demodicidosis with oral ivermectin and topical permethrin cream. J Am Acad Dermatol. 1999;41:775-7.

Serdar ZA, Yasar S. Efficacy of 1% terbinafine cream in comparison with 0.75% metronidazole gel for the treatment of papulopustular rosacea. Cutan Ocul Toxicol. 2011;30:124-8.

Kligman AM. Topical tretinoin for rosacea: a preliminary report. J Dermatol Treat. 1993;4:71-73.

Ertl GA, Levine N, Kligman AM. A comparison of the efficacy of topical tretinoin and low-dose oral isotretinoin in rosacea. Arch Dermatol. 1994;130:319-24.

Shanler SD, Ondo AL. Successful treatment of the erythema and flushing of rosacea using a topically applied selective alpha1-adrenergic receptor agonist, oxymetazoline. Arch Dermatol. 2007;143:1369-71.

Fowler J, Jarratt M, Moore A, , Meadows K, Pollack A, Steinhoff M, et al. Once-daily topical brimonidine tartrate gel 0.5% is a novel treatment for moderate to severe facial erythema of rosacea: results of two multicentre, randomized and vehicle-controlled studies. Br J Dermatol. 2012;166:633-41.

Sneddon IB. A clinical trial of tetracycline in rosacea. Br J Dermatol. 1966;78:649-652.

Sapadin AN, Fleischmajer R. Tetracyclines: nonantibiotic properties and their clinical implications. J Am Acad Dermatol. 2006;54:258-65.

Maibach H. Second generation tetracyclines, a dermatological overview: clinical uses and pharmacology. Cutis. 1991;48:411-7.

Theobald K, Bradshaw M, Leyden J. Anti-inflammatory doxycycline (40 mg contolled-release) confers maximum anti-inflammatory efficacy in rosacea. Skinmed. 2007;6:221-6.

McKeage K, Deeks ED. Doxycycline 40 mg capsules (30 mg immediaterelease/10 mg delayed-release beads): anti-inflammatory dose in rosacea. Am J Clin Dermatol. 2010;11:217-22.

Walker C, Puumala S, Golub LM, Stoner JA, Lee HM, Payne JB. Subantimicrobial dose doxycycline effects on osteopenic bone loss: microbial results. J Periodontol. 2007;78:1590-1601.

Del Rosso JQ, Webster GF, Kackson M, Rendon M, Rich P, Torok H, et al. Two randomized phase III clinical trials evaluating anti-inflammatory dose doxycycline (40-mg doxycycline, USP capsules) administered once daily for treatment of rosacea. J Am Acad Dermatol. 2007;56:791-802.

Fowler JF Jr. Combined effect of anti-inflammatory dose doxycycline (40-mg doxycycline, usp monohydrate controlled-release capsules) and metronidazole topical gel 1% in the treatment of rosacea. J Drugs Dermatol. 2007;6:641-5.

Bakar O, Demircay Z, Gurbuz O. Therapeutic potential of azithromycin in rosacea. Int J Dermatol. 2004;43:151.

Torresani C. Clarithromycin: a new perspective in rosacea treatment. Int J Dermatol. 1998;37:343-9.

Torresani C, Pavesi A, Manata GC. Clarithromycin versus doxycycline in the treatment of rosacea. Int J Dermatol. 1997;36:938-46.

Erdogan FG, Yurtsever P, Aksoy D, Eskioglu F. Efficacy of low-dose isotretinoin in patients with treatment-resistant rosacea. Arch Dermatol. 1998;134:884-5.

Hoting E, Paul E, Plewig G. Treatment of rosacea with Isotretinoin. Int J Dermatol. 1986;25:660-3.

Pye RJ, Burton JL. Treatment of rosacea by metronidazole. Lancet. 1976;1:1211-2.

Saihan EM, Burton JL. A double-blind trial of metronidazole versus oxytetracycline therapy for rosacea. Br J Dermatol. 1980;102:443-5.

Sharique KE, Najm RA, Al-Salman HN. Oral zinc sulphate in the treatment of rosaca: a double-blind, placebo-controlled study. Int J Dermatol. 2006;45:857-61.

Butterwick KJ, Butterwick LS, Han A. Laser and light therapies for acne rosacea. J Drugs Dermatol. 2006;5:35-9.

Taub AF. Treatment of rosacea with intense pulsed light. J Drugs Dermatol. 2003;2:254-9.

Kassir R, Kolluru A, Kassir M.Intense pulsed light for the treatment of rosacea and telangiectasias. J Cosmet Laser Ther. 2011;13:216-22.

Papageorgiou P, Clayton W, Norwood S, Chopra S, Rustin M. Treatment of rosacea with intense pulsed light: significant improvement and long-lasting results. Br J Dermatol. 2008;159:628-32.

Schroeter CA, Haaf-von Below S, Neumann HA. Effective treatment of rosacea using Intense pulsed light systems. Derm Surg .2005;31:1285-9.

Neuhaus IM, Zane LT, Tope WD. Comparative efficacy of nonpurpuragenic pulsed dye laser and intense pulsed light for erythematotelangiectatic rosacea. Dermatol Surg. 2009;35:920-8.

Downloads

Published

2018-07-24

Issue

Section

Review Articles